Search Results
Your search for ,NOt matches 22378 pages
Showing 22201 - 22250BRAF Mutation Status May Have Effect on Benefit of Aspirin Use for Patients with Colorectal Cancer
In two large studies, the association between aspirin use and risk of colorectal cancer was affected by BRAF mutation status, with regular aspirin use associated with a lower risk of BRAF wild-type colorectal cancer but not with risk of BRAF-mutated cancer. The findings, published today in JAMA,...
Lugano 2013: PET-guided Radiation Therapy Improves Survival in Patients with Advanced Diffuse Large B-cell Lymphoma
Residual masses are often detected on post-therapy computed tomography (CT) scans in patients with diffuse large B-cell lymphoma, and the potential role of consolidative radiation therapy in such cases remains undefined. An analysis of the use of PET-guided radiation therapy presented by Laurie H....
Lugano 2013: Ibrutinib Highly Active in Patients with Chronic Lymphocytic Leukemia with 17p Deletion
The 17p deletion in chronic lymphocytic leukemia (CLL) is associated with worse outcome in patients receiving standard chemotherapy. The Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib has shown durable antitumor activity in high-risk CLL. Adrian Wiestner, MD, PhD, of the National...
New Study Finds AICR Recommendations Cut Breast Cancer Risk
Postmenopausal women who follow at least five Recommendations for Cancer Prevention from the American Institute for Cancer Research (AICR) cut their risk of developing breast cancer by more than half, compared to those who meet none, suggests a new study that adds to previous research showing...
Chemotherapy-induced Neuropathy Has Long-term Effect on Colorectal Cancer Survivors
In a study reported in Journal of Clinical Oncology, Floortje Mols, PhD, of the Center of Research on Psychology in Somatic Diseases, Tilburg University, and colleagues assessed the prevalence and severity of chemotherapy-induced neuropathy and its affect on health-related quality of life in...
BTK Inhibitor Ibrutinib Produces High Response Rate in Relapsed/Refractory Mantle Cell Lymphoma
Ibrutinib is a first-in-class oral covalent inhibitor of Bruton’s tyrosine kinase (BTK), a mediator of the B-cell receptor signaling pathway implicated in the pathogenesis of B-cell cancers. As reported in The New England Journal of Medicine, Michael L. Wang, MD, of The University...
Two Bills before Congress Aim to Fight Breast Cancer and End Disparities in Care
Members of Congress are considering two bills that could advance cures for breast cancer and provide better education for women grappling with decisions about their treatment options. Accelerating the End of Breast Cancer Act Accelerating the End of Breast Cancer Act of 2013 (S. 865/H.R. 1830)...
High Rate of Durable Remissions with BTK Inhibitor Ibrutinib in Patients with Relapsed Chronic Lymphocytic Leukemia
Durable remissions are uncommon with current treatments for relapsed chronic lymphocytic leukemia (CLL). Bruton’s tyrosine kinase (BTK) is an essential component of B-cell receptor signaling that mediates interactions with the tumor microenvironment and promotes survival and proliferation of...
Researchers Identify and Map Signaling Pathway from EGFR to MCM7 Protein
Researchers have discovered and mapped the signaling network between two previously unconnected proteins, exposing a link that, if broken, could cut off cancer cell growth at its starting point. A team led by scientists at The University of Texas MD Anderson Cancer Center reported the tie between...
Investigators Identify Promising Biomarker for Predicting HPV-related Oropharyngeal Cancer
Researchers have found that antibodies against the human papillomavirus (HPV) may help identify individuals who are at greatly increased risk of HPV-related cancer of the oropharynx, In their study, at least one in three individuals with oropharyngeal cancer had antibodies to HPV, compared to...
Deep Sequencing Accurately Predicts Prolonged Survival in Multiple Myeloma Patients
A study by the Spanish Myeloma Group comparing the prognostic value of traditional response criteria and minimal residual disease measurement in patients with multiple myeloma found that a sequencing-based method called LymphoSIGHT and multiparameter flow cytometry analysis both accurately...
Follicular Lymphoma Cells Induce Changes in T-cell Gene Expression and Function, Show Prognostic Significance for Survival
It has been shown that CD4 and CD8 tumor-infiltrating lymphocytes in follicular lymphoma have impaired function and suppressed recruitment of critical signaling proteins to the immunologic synapse, and a number of studies have indicated the prognostic importance of the immune microenvironment in...
Study Shows HPV Vaccine Reduced Rate of Infection in Teenage Girls by 56%
A new government study investigating the prevalence of human papillomavirus (HPV) infections in females aged 14 to 59 before and after the introduction in 2006 of the HPV vaccine found that the rate of the HPV infection dropped by 56%, decreasing from 11.5% in 2006 to 5.1% in 2010 among female...
Virus Combination Effective Against Temozolomide-resistant Glioblastoma Multiforme
A combination of the myxoma virus and the immune suppressant rapamycin can kill glioblastoma multiforme, the most common and deadliest malignant brain tumor, according to new research published in Neuro-Oncology. Study lead author Peter A. Forsyth, MD, Chair of the Neuro-oncology Program at Moffitt ...
First-line Carboplatin plus Pemetrexed Improves Survival vs Pemetrexed Alone in Patients with Advanced NSCLC and Poor Performance Status
A significant proportion of patients with advanced non–small cell lung cancer (NSCLC) have poor performance status, and optimal clinical management of these patients has not been established. In an attempt to help define optimal chemotherapy in such patients, Mauro Zukin, MD, of Instituto...
Screening Colonoscopy Associated with Increased Survival Duration and Rates for Patients with Colon Cancer
Patients with colon cancer identified on screening colonoscopy appear to have lower-stage disease on presentation and better outcomes independent of their staging, according to a report published online today in JAMA Surgery. Since their introduction in 2000, National Institutes of Health...
Imatinib Active in Melanomas with KIT Mutation but Not KIT Amplification Alone
Mutations and amplifications in the KIT oncogene have been identified in mucosal and acral melanomas and in melanomas arising on chronically sun-damaged skin. In a multicenter phase II study reported in the Journal of Clinical Oncology, F. Stephen Hodi, MD, of Dana-Farber Cancer Institute, and...
Global Alliance Is Formed to Share Genomic Data
This month, an international group of over 70 research and health-care organizations, academic centers, and medical societies, including ASCO, signed a letter of intent to form a global alliance to make medicine more effective by consolidating the world’s databases of genomic information. The ...
PHARE Trial Fails to Establish Noninferiority of 6 vs 12 Months of Adjuvant Trastuzumab in Early HER2-positive Breast Cancer
The phase III open-label PHARE trial, conducted in 156 centers in France, examined whether 6 months of adjuvant trastuzumab (Herceptin) was noninferior to 12 months of treatment in women with early HER2-positive breast cancer. As reported by Xavier Pivot, MD, of University Hospital Jean-Minjoz,...
Acetyl-L-carnitine Ineffective for Taxane-related Peripheral Neuropathy
Various studies have suggested that acetyl-L-carnitine, a natural compound involved in neuronal protection, may be effective in preventing and treating sensory neuropathy. Dawn L. Hershman, MD, MS, of Columbia University Medical Center, and colleagues recently assessed whether daily...
Accountable Care Organizations May Be at Risk for New Medical Liabilities
The promotion of accountable care organizations, a crucial element in the Affordable Care Act, may result in liability risks, asserted authors H. Benjamin Harvey, MD, JD, a radiologist in the Department of Radiology at Massachusetts General Hospital, and I. Glenn Cohen, JD, Assistant Professor of...
ASCO 2013: Genomic Heterogeneity Can Lead to the Selection of ‘Incorrect’ Targeted Inhibitors
Genomic heterogeneity within tumors and among lesions varies widely, and “discordance among lesions could lead to the selection of the ‘incorrect’ targeted inhibitor,” according to David B. Solit, MD, of Memorial Sloan-Kettering Cancer Center, who spoke at the ASCO/American...
NCI Will No Longer Accept R01 and P01 Applications for Phase III Clinical Trials of Medical Interventions and Cancer Imaging Modalities
The National Cancer Institute (NCI) has announced that it will no longer accept investigator-initiated R01 and P01 applications that propose phase III clinical trials for cancer-related medical interventions or cancer imaging modalities. The policy change takes effect starting with the due date of...
FDA Approves New Silicone Gel-filled Breast Implant
The FDA recently approved the MemoryShape Breast Implant for breast augmentation in women at least 22 years old and for breast reconstruction in women of any age. The MemoryShape Breast Implants are manufactured by Mentor Worldwide LLC. The FDA’s approval is based on 6 years of data from 955 ...
Osteoporosis Drug Stops Growth of Breast Cancer Cells in Tamoxifen-resistant Tumors
A drug approved in Europe to treat osteoporosis has now been shown to stop the growth of breast cancer cells, even in cancers that have become resistant to current targeted therapies, according to a study presented at the Endocrine Society’s 95th Annual Meeting in San Francisco. The findings ...
Developmental Protein Plays Role in Spread of Cancer
A protein used by embryo cells during early development, and recently found in many different types of cancer, may serve as a switch regulating metastasis, according to researchers at the University of California, San Diego School of Medicine and UC San Diego Moores Cancer Center. The findings were ...
Human Genes May Not Be Patented, Rules the Supreme Court
The U.S. Supreme Court ruled unanimously on Thursday that isolated human genes may not be patented. However, the creation of synthetic forms of DNA, known as complementary DNA (cDNA), is eligible for patent protection. The decision resolves the question brought before the Supreme Court justices in...
Younger Age Does Not Significantly Impact Recurrence or Benefit from Trastuzumab in Early-stage HER2-positive Breast Cancer
Available data suggest that younger age is an independent risk factor for disease recurrence and death in women with breast cancer. However, there has not been adequate study of the interaction of age with human epidermal growth factor receptor 2 (HER2) status or anti-HER2 treatment. In an analysis ...
FDA Approves Denosumab to Treat Giant Cell Tumor of the Bone
The U.S. Food and Drug Administration (FDA) today expanded the approved use of denosumab (Xgeva) to treat adults and some adolescents with giant cell tumor of the bone, a rare and usually noncancerous tumor. Denosumab, which was granted orphan product designation, was reviewed under the FDA’s ...
Newly Identified Markers May Predict Who Will Respond to Breast Cancer Prevention Therapy
Single nucleotide polymorphisms (SNPs) in or near the genes ZNF423 and CTSO were associated with breast cancer risk among women who underwent prevention therapy with tamoxifen and raloxifene, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research. ...
ASCO 2013: First Prospective Trial Shows Molecular Profiling Timely for Tailoring Therapy
A clinical trial has shown that patients and their physicians are eager to jump into the next generation of cancer care: analysis of an individual’s tumor to find and target genetic mutations that drive the cancer. Results of the study, CUSTOM, were presented at the 2013 ASCO Annual Meeting...
Critically Ill Patients with Hematologic Malignancies Admitted to ICU Have Good Survival, Disease Control, and Quality of Life
A large prospective multicenter cohort study in France and Belgium, reported by the Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique, has shown that critically ill patients with hematologic malignancies admitted to the intensive care unit (ICU) have good survival,...
ASCO 2013: Top Five Things Oncologists Need to Know about Cancer in Older Adults
A workforce shortage of geriatricians and other health professionals trained and certified in caring for older patients with cancer is colliding with the aging of the population and the increasing number of older Americans with cancer. After describing factors contributing to these dual challenges, ...
CMS Says It Lacks Authority to Roll Back Sequestration Cuts to Medicare Payments for Part B Cancer Drugs
According to a June 3 letter from the Centers for Medicare and Medicaid Services (CMS), there will be no reprieve in the 2% ($11.08 billion) reduction to Medicare providers and hospitals mandated by the federal budget sequestration. The letter by CMS Acting Administrator Marilyn Tavenner was in...
Radioimmunotherapy/Chemotherapy Combination Could Extend Survival in Some Patients with Advanced Lymphoma
A new patient protocol for aggressive and recurrent lymphoma that combines intensive chemotherapy and radioimmunotherapy showed encouraging overall survival rates in some patients preparing for autologous bone marrow transplant, reported researchers at the 2013 Annual Meeting of the Society of...
Sequential PET/MRI Predicts Chemotherapy’s Ability to Improve Survival in Patients with Advanced Breast Cancer
For patients with advanced breast cancer, positron-emission tomography (PET) and magnetic resonance imaging (MRI) can improve quality of life and survival by providing physicians with information on the effectiveness of chemotherapy prior to surgery, according to researchers presenting at the 2013...
Reducing Unnecessary and High-dose Pediatric CT Scans Could Cut Future Cancers by More than Half
A study examining trends in x-ray computed tomography (CT) use in children in the United States has found that reducing unnecessary scans and lowering the doses for the highest-dose scans could lower the overall lifetime risk of future imaging-related cancers by 62%. The research was published...
National Institutes of Health Issues Projected Impact of Sequestration on Programs
Earlier this month, the National Institutes of Health (NIH) released its updated projections of reductions in programs due to the deficit-budget mechanism known as sequestration, which took effect on March 1, 2013. The sequestration law requires NIH to cut 5%, or $1.55 billion, of its fiscal year...
ASCO 2013: Surveillance Sufficient Follow-up for Most Patients with Stage I Seminoma
Surveillance appears to be sufficient for men with stage I seminoma treated with orchiectomy, sparing patients from side effects of adjuvant radiation or chemotherapy. In a long-term study presented at the 2013 ASCO Annual Meeting (Abstract 4502), 99.5% of men followed by surveillance alone...
Some Stage II/III HER2-positive Tumors May Be Treated with Targeted Therapy without Chemotherapy
Results from a multicenter phase II study of patients with locally advanced HER2-positive breast cancer who receive targeted therapy with trastuzumab (Herceptin) and lapatinib (Tykerb) “support the hypothesis that selected patients with HER2-positive tumors may not need...
FDA Grants Orphan Drug Status for Novel Targeted Therapy for the Treatment of Rare Hematologic Cancer
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to Stemline Therapeutics' SL-401 for the treatment of blastic plasmacytoid dendritic cell neoplasm, a rare and aggressive hematologic malignancy for which there is no effective treatment. SL-401 also has Orphan Drug...
FDA Clears Multicenter Trial of Treatment for Chemotherapy-related Hair Loss
The FDA has approved initiation of a multicenter trial of the DigniCap System, a scalp-cooling device for chemotherapy-related hair loss. The trial is the second and final phase of study for the DigniCap System. A pilot study previously conducted by researchers at the University of California San...
Potential New Way to Suppress Tumor Growth Discovered
Researchers at the University of California, San Diego, School of Medicine, and University of Rochester Medical Center have identified a new mechanism that appears to suppress tumor growth, opening the possibility of developing a new class of anticancer drugs. The findings were published in this...
ASCO 2013: Novel Heat Shock Protein Inhibitor Effective in Combination with Docetaxel as Second-line Therapy for Advanced Lung Cancer
A large randomized phase II study, GALAXY-1, found that a novel heat shock protein (Hsp) 90 inhibitor, ganetespib, when combined with docetaxel in second-line therapy, leads to longer overall survival compared to standard second-line docetaxel alone in patients with advanced lung adenocarcinoma...
ASCO 2013: More than 20% of African American Women Carry Inherited Mutations in at Least One Breast Cancer Susceptibility Gene
A genomic profiling study of African American women with breast cancer found that about one in five carries an inherited abnormality in at least 1 of 18 genes associated with breast cancer susceptibility. Such mutations were more prevalent among women with aggressive triple-negative breast cancer,...
ASCO 2013: Weekly Paclitaxel Is Less Toxic but as Effective for Women with Higher-risk Early-stage Breast Cancer
Low-dose weekly administration of paclitaxel resulted in equal progression-free survival but reduced overall toxicity compared to every-2-week dose-dense administration for women with higher-risk early-stage breast cancer who have undergone surgery, according to a phase III randomized trial....
Cytomegalovirus Might Speed Brain Cancer Growth
A study led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) and Dana-Farber Cancer Institute suggests that cytomegalovirus, a virus that infects most adults in the United...
ASCO 2013: Adapting to Ongoing Shortages of Common Cancer Drugs
A survey of 214 U.S. oncologists and hematologists found that more than 80% encountered cancer drug shortages between March and September of 2012, and many reported that shortages affected the quality of patient care they were able to provide. As physicians were forced to substitute more expensive...
ASCO 2013: Cervical Cancer Screening Using Visual Inspection with Vinegar Reduces Mortality by 31% in Large Study in India
Cervical cancer mortality was reduced by 31% over a period of 15 years among women screened with biennial visual inspection with acetic acid (VIA), or vinegar, delivered by primary health workers in a large randomized study conducted among 150,000 women in India. The researchers estimate this...
ASCO 2013: Sorafenib Stalls Growth of Treatment-resistant Differentiated Thyroid Cancer
A randomized phase III study found that the targeted drug sorafenib (Nexavar) stalls disease progression by 5 months in patients with metastatic differentiated thyroid cancer that has progressed despite standard radioactive iodine therapy. If approved in this setting by the U.S. Food and Drug...
